HHS is distributing the experimental antiviral remdesivir to hospitals hardest hit by COVID-19
Gilead Sciences committed to supplying approximately 607,000 vials over the next six weeks to treat an estimated 78,000 hospitalized patients.
Read the full post on News Feed
